|Awarded On||February 16, 2022|
|Title||Development of Next-Generation Estrogen Receptor Mutant Inhibitors for Endocrine Resistant Metastatic Breast Cancer|
|Award Mechanism||Individual Investigator|
|Institution/Organization||Baylor College of Medicine|
|Principal Investigator/Program Director||Murugesan Palaniappan|
Breast cancer (BC) is normally dependent upon the estrogen hormone that interacts with the estrogen receptor (ER) expressed in BC cells. Drugs designed to inhibit ER activity or block estrogen synthesis in the body are currently being used in the clinic to treat BC and have been quite successful in controlling breast cancer progression for the majority of patients. Regrettably, however, BC often becomes resistant to these endocrine therapies, leading to endocrine-resistant metastatic breast cancer (MBC), a very aggressive cancer that leads to death.
Recent large-scale genomic studies have revealed that a series of activating mutations in the ER gene (ESR1) in endocrine-resistant MBC patients...